# Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

> **NCT01515527** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 160 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT01515527
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2012-02-07
- **Primary completion:** 2028-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01515527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01515527, "Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01515527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*